{"nctId":"NCT01370005","briefTitle":"12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-06"},"conditions":["Diabetes Mellitus, Type 2","Hypertension"],"count":825,"armGroups":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: BI 10773"]},{"label":"BI 10773 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients \\>=18 years with type 2 diabetes\n2. HbA1c of \\>= 7.0% (53 mmol/mol) and =\\< 10% (86 mmol/mol)\n3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99 mmHg\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycaemia with a glucose level \\>240 mg/dl (\\>13.3 mmol/L) after an overnight fast before randomization\n2. Known or suspected secondary hypertension\n3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline","description":"Change from baseline in HbA1c after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.60"},{"groupId":"OG001","value":"-0.59","spread":"0.63"},{"groupId":"OG002","value":"-0.63","spread":"0.62"}]}]}]},{"type":"PRIMARY","title":"Mean 24-hour Systolic Blood Pressure Change From Baseline","description":"Change from baseline of mean 24-hour systolic blood pressure (SBP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"8.25"},{"groupId":"OG001","value":"-2.99","spread":"8.86"},{"groupId":"OG002","value":"-3.59","spread":"9.30"}]}]}]},{"type":"SECONDARY","title":"Mean 24-hour Diastolic Blood Pressure Change From Baseline","description":"Change from baseline in mean 24-hour diastolic blood pressure (DBP) after 12 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"5.06"},{"groupId":"OG001","value":"-1.10","spread":"4.96"},{"groupId":"OG002","value":"-1.32","spread":"4.96"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With HbA1c <7%","description":"Proportion of patients with HbA1c \\<7% after 12 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline","description":"Change from baseline in FPG after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.19","spread":"38.29"},{"groupId":"OG001","value":"-15.23","spread":"33.32"},{"groupId":"OG002","value":"-24.45","spread":"35.38"}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline","description":"Change from baseline in body weight after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.55"},{"groupId":"OG001","value":"-1.67","spread":"2.38"},{"groupId":"OG002","value":"-2.16","spread":"2.38"}]}]}]},{"type":"SECONDARY","title":"Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline","description":"Change from baseline in daytime mean SBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"8.74"},{"groupId":"OG001","value":"-3.40","spread":"9.55"},{"groupId":"OG002","value":"-4.12","spread":"9.55"}]}]}]},{"type":"SECONDARY","title":"Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline","description":"Change from baseline in daytime mean DBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"5.36"},{"groupId":"OG001","value":"-1.28","spread":"5.41"},{"groupId":"OG002","value":"-1.58","spread":"5.35"}]}]}]},{"type":"SECONDARY","title":"Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline","description":"Change from baseline in nighttime mean SBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"10.22"},{"groupId":"OG001","value":"-2.22","spread":"10.21"},{"groupId":"OG002","value":"-2.47","spread":"11.09"}]}]}]},{"type":"SECONDARY","title":"Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline","description":"Change from baseline in nighttime mean DBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"6.80"},{"groupId":"OG001","value":"-0.80","spread":"6.21"},{"groupId":"OG002","value":"-0.75","spread":"6.32"}]}]}]},{"type":"SECONDARY","title":"Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline","description":"Change from baseline in Trough Mean Seated SBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"11.92"},{"groupId":"OG001","value":"-4.73","spread":"12.54"},{"groupId":"OG002","value":"-5.45","spread":"12.43"}]}]}]},{"type":"SECONDARY","title":"Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline","description":"Change from baseline in trough mean seated DBP after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"6.58"},{"groupId":"OG001","value":"-3.18","spread":"7.10"},{"groupId":"OG002","value":"-3.01","spread":"7.05"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Reaching Blood Pressure <130/80 mmHg","description":"Proportion of patients reaching blood pressure \\<130/80 mmHg after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight","description":"A composite endpoint of the following conditions at week 12 compared to baseline (all 3 fulfilled): reduction of HbA1c from baseline of at least 0.5%, reduction of systolic blood pressure \\> 3 mmHg from baseline and reduction of weight from baseline \\> 2%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"218","spread":null}]}]}]},{"type":"SECONDARY","title":"Orthostatic Blood Pressure","description":"Orthostatic blood pressure (BP) at baseline and after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"219","spread":null},{"groupId":"OG002","value":"208","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"192","spread":null},{"groupId":"OG002","value":"183","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Confirmed Hypoglycaemic Adverse Events","description":"Number of participants with confirmed hypoglycaemic adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":272},"commonTop":["Nasopharyngitis","Hypoglycaemia","Pollakiuria","Thirst"]}}}